Impact of antiphospholipid and antinuclear antibodies in coronary artery disease progression
This study does not support a significant role for aPL or ANA in the development or progression of CAD. These findings should be interpreted as hypothesis-generating, and larger, prospective multicenter studies with repeated antibody measurements are required to clarify these associations.
Authors
- José L. Hernández (ORCID: https://orcid.org/0000-0002-6585-8847)
- José M. de la Torre Hernández (ORCID: https://orcid.org/0000-0003-4570-8902)
- Alejandra Comins‐Boo (ORCID: https://orcid.org/0000-0001-8353-6211)
- Juan Irure‐Ventura (ORCID: https://orcid.org/0000-0003-2315-8671)
- Víctor Manuel Martínez-Taboada (ORCID: https://orcid.org/0000-0003-2916-8491)
- Marcos López‐Hoyos (ORCID: https://orcid.org/0000-0003-0562-427X)
- Tamara García Camarero (ORCID: https://orcid.org/0000-0002-4088-8310)
Institutions
- Universidad de Cantabria (ES)
- Instituto de Investigación Marqués de Valdecilla (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1632642
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00